Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 2, 2017, Pages

  Robertson, Lindsay ^a   Jones, Lauren E ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT;

BLEEDING; COMPARATIVE EFFECTIVENESS; DEEP VEIN THROMBOSIS; FOLLOW UP; HUMAN; INCIDENCE; LUNG EMBOLISM; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; META ANALYSIS; PULMONARY EMBOLISM; SUBCUTANEOUS DRUG ADMINISTRATION; VENOUS THROMBOSIS;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; VENOUS THROMBOSIS;

EID: 85012060183     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001100.pub4     Document Type: Review

References (98)

1. Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999;50(10):781-7. [3050252]
2. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine 2001;344(9):626-31. [3050254]
3. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine 2000;160(22):3431-6. [3050256]
4. The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. Blood 1996; Vol. 88:626a. [3050258]
5. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine 1997;337(10):657-62. [3050259]
6. ten Cate JW, Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. Journal of Vascular and Interventional Radiology 1998;9:178. [3050257]
7. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard PH, et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. New England Journal of Medicine 1998;338(7):409-15. [3050261]
8. Faivre R, Neuhart E, Kieffer Y, Toulemonde F, Bassand JP, Maurat JP. Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thrombosis and Haemostasis 1987;58(1):Abstract 430. [3050263]
9. Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, et al. A new treatment of deep vein thrombosis: low molecular weight heparin fractions. Randomised study [Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee]. Presse Medicale 1988;17(5):197-200. [3050264]
10. Fiessinger JN, Fernandez ML, Gatterer E, Ohlsson CG. Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis 1994;24(Suppl 1):Abstract 44. [3050266]
11. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis 1996;76(2):195-9. [3050267]
12. Findik S, Erkan ML, Selçuk MB, Albayrak S, Atici AG, Doru F. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration 2002;69(5):440-4. [3050269]
13. Goldhaber SZ, Morrison RB, Diran LL, Creager MA, Lee TH Jr. Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Archives of Internal Medicine 1998;158(21):2325-8. [3050273]
14. Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Buller HR. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis 2000;83(5):652-6. [3050275]
15. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Archives of Internal Medicine 2000;160(2):229-36. [3050277]
16. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine 1992;326(15):975-82. [3050278]
17. Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P, Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thrombosis and Haemostasis 2003;89(4):674-80. [3050280]
18. Kirchmaier CM, Wolf H, Schafer H, Ehlers B, Breddin HK. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. International Angiology 1998;17(3):135-45. [3050282]
19. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van den Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. New England Journal of Medicine 1996;334(11):682-7. [3050284]
20. Leizorovicz A. Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency - the IRIS trial. Blood 2008; Vol. 112, issue 11:434. [3050288]
21. Leizorovicz A, Siguret V, Mottier D. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep((R)) in Renal Insufficiency Study (IRIS). Thrombosis Research 2011;128(1):27-34. [3050286]
22. NCT00277394 . Innohep© in elderly patients with impaired renal function treated for acute deep vein thrombosis. clinicaltrials.gov/ct/show/NCT00277394 2007. [3050287]
23. Siguret V, Deudon C, Golmard J, Leizorovicz A, Pautas E, Gouin-Thibault I. Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial. Journal of Thrombosis and Haemostasis 2013;11 (Suppl 2):805. [5086386]
24. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 1996;334(11):677-81. [3050290]
25. Holmstrom M, Lindmarker P, Granqvist S, Johnsson H, Lockner D. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis. Thrombosis and Haemostasis 1997;78(2):803-7. [3050292]
26. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin (TM) with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis 1994;72(2):186-90. [3050293]
27. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis 1992;68(1):14-8. [3050295]
28. Luomanmaki K and the Finnish Multicentre Group, et al. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT. Haemostasis 1994;24(Suppl 1):Abstract 248. [3050297]
29. Luomanmaki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine 1996;240(2):85-92. [3050298]
30. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine 2001;134(3):191-202. [3050300]
31. Spiro TE, The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Thrombosis and Haemostasis 1997;374(Suppl):Abstract SC 1527. [3050301]
32. de Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorensen SV. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Archives of Internal Medicine 2000;160(20):3160-5. [3050302]
33. Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B, et al. Subcutaneous low-molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thrombosis and Haemostasis 1995;74(6):1432-5. [3050304]
34. Moreno-Palomares JJ, Fisac-Herrero RM, Herrero Domingo A, Ferreira-Pasos EM, Grasa J, Reverte Cejudo D. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Anales de Medicina Interna 2001;18(7):364-8. [3050306]
35. Ninet J, Bachet P, Prandoni P, Ruol A, Vigo M, Barret A, et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis 1991;65(3):251-6. [3050308]
36. Pérez de Llano LA, Baloira Villar A, Veres Racamonde A, Veiga F, Golpe, Gomez R, et al. Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism. Archivos de Bronconeumologia 2003;39(8):341-5. [3050310]
37. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339(8791):441-5. [3050312]
38. Prandoni P, Carnovali M, Marchiori A. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine 2004;164:1077-83. [3050271]
39. Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Grave M, Patek F, et al. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis 2003;90(2):252-9. [3050314]
40. Riess H, Koppenhagen K, Tolle AR, Kemkes-Matthes B, Grave M, Harenberg J, et al. Fixed-dose body weight-independent subcutaneous LMW-heparin (LMWH) certoparin is equally effective to adjusted-dose intravenous uf-heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT). Annals of Hematology 2001;80 Suppl 1:A56. [3050315]
41. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Archives of Internal Medicine 1993;153(13):1541-6. [3050317]
42. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J-P, Azarian R, et al. for the THESEE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine 1997;337(10):663-9. [3050319]
43. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY216 (fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. Circulation 1992;85(4):1380-9. [3050321]
44. Aiach M, Fiessinger JN, Vitoux JF, Le Querrec A, Gouault-Heilmann M, et al. Deep vein thrombosis treatment. A comparative study: subcutaneous Fragmin versus unfractionated heparin administered by continuous infusion. Multicentre trial. [Traitement des thromboses veineuses profondes constituees. Etude comparative d'un fragment d'heparine de bas poids moleculaire (Fragmine) administree par voie sous-cutanee et de l'heparine standard administree par voie intraveineuse continue. Etude multicentrique. [French]]. Revue de Medecine Interne 1989;10(4):375-81. [3050323]
45. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Circulation 1989;80(4):935-40. [3050325]
46. Banga JD, de Valk HW, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen OJAT, et al. A dose finding study of subcutaneous heparinoid Oragaran (ORG 10172) twice daily compared to continuous intravenous unfractionated heparin in the treatment of venous thromboembolism. Thrombosis and Haemostasis 1993;69:545 Abstract 20. [3050327]
47. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin Kabi 2165 and standard heparin in the intravenous treatment of deep vein thrombosis. Thrombosis and Haemostasis 1985;54(4):813-7. [3050329]
48. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thrombosis and Haemostasis 1990;64(4):506-10. [3050331]
49. de Valk HW, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen OJAT, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomised controlled trial. Annals of Internal Medicine 1995;123(1):1-9. [3050333]
50. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. European Journal of Clinical Pharmacology 1990;39(2):107-12. [3050335]
51. Harenberg J, Huck K, Stehle G, Mall K, Schwarz A, Heene DL. Prospective randomized, controlled study on the treatment of deep venous thrombosis using low molecular weight heparin compared with unfractionated heparin. Thrombosis and Haemostasis 1989;62:356 Abstract No. 1106. [3050337]
52. Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin. Seminars in Thrombosis and Hemostasis 2001;27:513-8. [3050338]
53. Harenberg J, Riess H, Fischer H, Brom J, Eidinger GW. Initial treatment of patients with acute deep-vein thrombosis using 8.000 IU bid low-molecular-weight heparin certoparin - A 24 months follow up. Journal of Thrombosis and Haemostasis 2005;3(1):Abstract No. P1021. [3050339]
54. Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle CE, Mall K, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 1990;20 Suppl 1:205-19. [3050341]
55. Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL. Dosage, anticoagulant and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Seminars in Thrombosis and Hemostasis 1997;23(1):83-90. [3050342]
56. Harenberg J, Breddin HK, Kirchmaier CM, Tolle A. Does fixed dose body weight independent subcutaneous low-molecular-weight heparin improve the Marder score compared to adjusted dose unfractionated heparin in the treatment of venous thrombosis. Annals of Hematology 2000;79 Suppl 1:A84. [3050344]
57. Holm HA, Ly B, Handeland GF, Abildegaard U, Arnesen KE, Gottschalk P, et al. Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16 Suppl 2:30-7. [3050346]
58. Kearon C, Ginsberg JJ, Julian J, Douketis J, Solymoss S, Ockelford P, et al. Fixed-dose, weight-adjusted, unfractionated heparin (UFH) given subcutaneously (sc) without laboratory monitoring for acute treatment of venous thromboembolism (VTE): Randomized comparison with low-molecular-weight-heparin (LMWH). Blood 2004; Vol. 104, issue 11:Abstract 707. [3050348]
59. Kearon C, Ginsberg JS, Julian J, Douketis J, Solymoss S, Ockelford P, et al. Acute treatment of venous thromboembolism (VTE) with fixed-dose, weight-adjusted, unfractionated heparin (UFH) given subcutaneously (sc) without laboratory monitoring: randomized comparison with low-molecular-weight-heparin (LMWH). Journal of Thrombosis and Haemostasis 2005; Vol. 3, issue 1:Abstract number: OR147. [3050349]
60. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, et al. Comparison of fixed-dose weight-adjusted-unfractionated heparin and low-molecular weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296:935-42. [3050350]
61. Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. A comparison between low molecular weight heparin (LMWH, KABI 2165) and standard heparin in the intravenous treatment of deep vein thrombosis (DVT). Thrombosis and Haemostasis 1985;54(4):813-7. [3050352]
62. Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 1986;16 Suppl 2:25-9. [3050354]
63. Ly B, Arnesen KE, Holm HA, Handeland GF, Abilgaard U. Subcutaneous LMW or unfractionated heparin in DVT: A randomized, double blind study with dose adjustments according to heparin concentration in plasma. Thrombosis and Haemostasis 1985;54(1):Abstract No. 91. [3050356]
64. Monreal M, Lafoz E, Vedia C, Roncales J. Comparison of subcutaneous unfractioned heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis 1993;69(649):Abstract No. 383. [3050358]
65. Monreal M, Lafoz E, Olive A, de Rio L. Comparison of subcutaneous unfractioned heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis 1994;71(1):7-11. [3050360]
66. Notarbartolo A, Salanitri G, Davi G, Averna M, Barbagallo C, Catalano I. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Praxis Med 1988;9:393-405. [3050362]
67. Quiros M. Use of heparin of low molecular weight in the ambulatory handling of patients with deep venous thrombosis. Comparative study: heparin nondivided versus low molecular weight heparin. Revista costarricense de cardiologia 2001;3(2):8-13. [3050364]
68. Riess H, Becker LK, Melzer N, Harenberg J. Treatment of deep vein thrombosis in patients with pulmonary embolism: Subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin. Blood Coagulation & Fibrinolysis 2014;25(8):838-44. [3050366]
69. Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A. No accumulation of the peak anti-Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. Journal of Thrombosis and Haemostasis 2011;9(10):1966-72. [3050368]
70. Stricker H, Marchetti O, Haeberli A, Mombelli G. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. Thrombosis and Haemostasis 1999;82(4):1227-31. [3050370]
71. Tedoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clinical Trials and Meta-analysis 1993;28(4-5):215-25. [3050372]
72. Ucar EY, Akgun M, Araz O, Tas H, Kerget B, Meral M, et al. Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pulmonary thromboembolism after thrombolytic treatment: randomized controlled parallel group study. Lung. Springer New York LLC, 2015; Vol. 193, issue 1:121-7. [3050374]
73. Vogel G, Machulik M. Efficacy and safety of a low molecular weight heparin (LMW-heparin Sandoz) in patients with deep vein thrombosis. Thrombosis and Haemostasis 1987;58 Suppl:Abstract No. 427. [3050376]
74. Zanghi M, Morici V, Costanzo M, Astuto L, Salanitri G. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. Journal of International Medical Research 1988;16(6):474-84. [3050378]
75. NCT00796692 . Nadroparin for the initial treatment of pulmonary thromboembolism (NATSPUTE). ClinicalTrials.gov (first received 20 November 2008). [5086388]
76. Buller HR, Lensing AWA, Hirsh J, ten Cate JW. Deep venous thrombosis: new noninvasive tests. Thrombosis and Haemostasis 1991;66(1):133-9.
77. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statistics in Medicine 1987;6(3):245-50.
78. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
79. Diaz JP, Soto Molina H, Marquez M, Escobar Juarez Y. Low-molecular-weight heparin in treatment of deep-vein thrombosis: A network meta-analysis. Value in Health 2015;18(3):A31.
80. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal 2008;336(7650):924-6.
81. Higgins JP, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
82. Higgins JPT, Altman DG, Sterne JAC, editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
83. Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chirurgica Scandinavica 1990;156 Suppl 556:42-50.
84. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79(1):1-17.
85. Huisman MV, Buller HR, ten Cate JW, van Royen EA, Vreeken J, Kersten MJ, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep vein thrombosis. Chest 1989;95(3):498-502.
86. Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, et al. Pulmonary angiography, ventilation lung scanning, and venography for suspected pulmonary embolism with abnormal perfusion lung scan. Annals of Internal Medicine 1983;98(6):891-9.
87. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S.
88. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
89. NICE . Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. www.nice.org.uk/guidance/cg144 (accessed 15 November 2016).
90. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340(8812):152-6.
91. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
92. Schulman S, Kearon C, and the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis 2005;3(4):692-4.
93. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
94. Turpie AGG, Chin BSP, Lip GYH. Venous thromboembolism: treatment strategies. British Medical Journal 2002;325(7370):948-50.
95. van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Buller HR, Koopman MMW, et al. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis. An economic evaluation. Thrombosis and Haemostasis 1998;79(2):259-63.
96. Erkens PMG, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD001100.pub3]
97. van den Belt AGM, Prins MH, Lensing AWA, Castro AA, Clark OAC, Atallah AN, Burihan E. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD001100]
98. van Dongen CJ, van den Belt AGM, Prins MH, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD001100.pub2]